# IFN- $\alpha/\beta R\alpha$ (m): 293T Lysate: sc-120957



The Power to Question

## **BACKGROUND**

The type I interferons (IFNs),  $\alpha$  and  $\beta$ , are a group of structurally and functionally related proteins that are induced by either viruses or double stranded RNA and defined by their ability to confer an antiviral state in cells. The  $\alpha$  and  $\beta$  IFNs appear to compete with one another for binding to a common cell surface receptor while immune IFN (IFN- $\gamma$ ) binds to a distinct receptor. The latter protein, IFN- $\alpha$ R, is only weakly responsive to type I interferons in contrast to IFN- $\alpha/\beta$ R, which binds to and responds effectively to IFN- $\beta$  and to several of the IFN- $\alpha$  subtypes. Moreover, IFN- $\alpha/\beta$ R is physically associated with the cytoplasmic tyrosine kinase JAK1 and thus, in addition to ligand binding, appears to be functionally involved in signal transduction. The IFN- $\gamma$  receptor complex consists of an  $\alpha$  subunit (IFN- $\gamma$ R $\alpha$ ) and a  $\beta$  subunit that is 332 amino acids in length (mouse) and 337 amino acids in length (human).

## **REFERENCES**

- 1. Branca, A.A., et al. 1981. Evidence that type I and II interferons have different receptors. Nature 294: 768-770.
- 2. Orchansky, P., et al. 1984. Type I and type II interferon receptors. J. Interferon Res. 4: 275-282.
- Novick, D., et al. 1987. The human interferon-γ receptor, purification, characterization and preparation of antibodies. J. Biol. Chem. 262: 8483-8487.
- 4. Aguet, M., et al. 1988. Molecular cloning and expression of the human interferon-γ receptor. Cell 55: 273-280.
- 5. Soh, J., et al. 1994. Identification and sequence of an accessory factor required for activation of the human interferon- $\gamma$  receptor. Cell 76: 793-802.
- Hemmi, S., et al. 1994. A novel member of the interferon receptor family complements functionality of the murine interferon-γ receptor in human cells. Cell 76: 803-810.
- 7. Novick, D., et al. 1994. The human interferon- $\alpha/\beta$  receptor: characterization and molecular cloning. Cell 77: 391-400.

# **CHROMOSOMAL LOCATION**

Genetic locus: Ifnar1 (mouse) mapping to 16 C3.3.

## **PRODUCT**

IFN- $\alpha/\beta R\alpha$  (m): 293T Lysate represents a lysate of mouse IFN- $\alpha/\beta R\alpha$  transfected 293T cells and is provided as 100  $\mu g$  protein in 200  $\mu l$  SDS-PAGE buffer.

### **STORAGE**

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

# **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

# **APPLICATIONS**

IFN- $\alpha/\beta R\alpha$  (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive IFN- $\alpha/\beta R\alpha$  antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

IFN- $\alpha/\beta R\alpha$  (E-12): sc-393089 is recommended as a positive control antibody for Western Blot analysis of enhanced mouse IFN- $\alpha/\beta R\alpha$  expression in IFN- $\alpha/\beta R\alpha$  transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

# **RECOMMENDED SUPPORT REAGENTS**

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

#### DATA



IFN- $\alpha$ /βR $\alpha$  (E-12): sc-393089. Western blot analysis of IFN- $\alpha$ /βR $\alpha$  expression in non-transfected: sc-117752 (**A**) and mouse IFN- $\alpha$ /βR $\alpha$  transfected: sc-120957 (**B**) 293T whole cell Ivsates.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.